Alto Neuroscience (NYSE:ANRO) Announces Quarterly Earnings Results

Key Points

• Alto Neuroscience reported quarterly EPS of $0.65 loss, beating the consensus estimate of a $0.73 loss by $0.08.
• Shares rose to $29.12, near their 52-week high of $29.70, while the company reported a $1.02 billion market capitalization and strong liquidity ratios.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $35.25, although ratings range from “Strong Sell” to “Buy.” Several institutional investors also increased their positions in the company.

Alto Neuroscience (NYSE:ANRO - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08, FiscalAI reports.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO traded up $0.34 on Wednesday, hitting $29.12. The company had a trading volume of 277,788 shares, compared to its average volume of 365,603. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.02 billion, a PE ratio of -12.03 and a beta of 1.06. Alto Neuroscience has a 52-week low of $3.02 and a 52-week high of $29.70. The business has a 50 day moving average of $25.24 and a 200 day moving average of $22.48.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ANRO shares. Bank of America began coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They set a "buy" rating and a $35.00 price target on the stock. Robert W. Baird decreased their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating on the stock in a report on Monday, May 18th. Wedbush upped their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a "neutral" rating in a research report on Thursday, May 14th. Wolfe Research started coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an "outperform" rating for the company. Finally, Zacks Research cut Alto Neuroscience from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 22nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.25.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd raised its position in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company's stock valued at $371,000 after buying an additional 5,078 shares during the last quarter. Ikarian Capital LLC grew its stake in Alto Neuroscience by 368.2% in the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company's stock worth $9,167,000 after acquiring an additional 405,000 shares during the period. Vestal Point Capital LP raised its holdings in Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock valued at $44,233,000 after acquiring an additional 1,535,000 shares during the last quarter. Wellington Management Group LLP acquired a new position in Alto Neuroscience in the 4th quarter valued at $1,228,000. Finally, Millennium Management LLC lifted its stake in shares of Alto Neuroscience by 99.5% during the 4th quarter. Millennium Management LLC now owns 629,985 shares of the company's stock worth $11,214,000 after purchasing an additional 314,227 shares during the period.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source